World Health Organization Raises Warning Over Acute Shortage of Weight-Loss Jabs

Less than one in 10 patients who could benefit from weight-loss injections like Wegovy are able to get them, states the WHO as it issues its initial recommendations on the medications.

Given in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just access to these injectable treatments.

According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"Our new guidance recognises that excess weight is a lifelong illness that can be addressed with holistic and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread availability to the treatments that can help people shift considerable weight, says the organization.

Skinny Jab Supply Crisis

Even in the current best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, per the health organization.

The recommendation urges governments and firms to widen access, via strategies including patent sharing.

A patent on a key compound – the core component of the drug Wegovy – is scheduled to end in multiple nations in 2026.

How Weight-Loss Injections Operate

GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so users reduce food intake.

Individuals typically see weight reduction after several weeks of starting on the regular doses.

Evidence points to users may put most of the weight back on within a year of halting the treatment, when their normal appetite resume.

Being overweight or obese raises your likelihood for contracting diseases, like diabetes, cardiovascular issues, brain attack, and specific cancers.

Excess weight affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, per the health agency.